109 related articles for article (PubMed ID: 12502983)
1. Systemic inflammation leads to resistance to atracurium without increasing membrane expression of acetylcholine receptors.
Fink H; Luppa P; Mayer B; Rosenbrock H; Metzger J; Martyn JA; Blobner M
Anesthesiology; 2003 Jan; 98(1):82-8. PubMed ID: 12502983
[TBL] [Abstract][Full Text] [Related]
2. Nitric oxide is not a mediator of inflammation-induced resistance to atracurium.
Fink H; Bogdanski R; Luppa P; Martyn JAJ; Blobner M
Anesth Analg; 2005 Nov; 101(5):1362-1367. PubMed ID: 16243995
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats.
Mayer B; Fink H; Bogdanski R; Stadler J; Blobner M
Eur J Anaesthesiol; 2001 Sep; 18(9):599-604. PubMed ID: 11553255
[TBL] [Abstract][Full Text] [Related]
4. Continuous administration of pyridostigmine improves immobilization-induced neuromuscular weakness.
Frick CG; Helming M; Martyn JA; Blobner M; Fink H
Crit Care Med; 2010 Mar; 38(3):922-7. PubMed ID: 20009758
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of botulinum toxin on neuromuscular function.
Frick CG; Richtsfeld M; Sahani ND; Kaneki M; Blobner M; Martyn JA
Anesthesiology; 2007 Jun; 106(6):1139-46. PubMed ID: 17525589
[TBL] [Abstract][Full Text] [Related]
6. Resistance to atracurium in rats with experimental inflammation: role of protein binding.
García E; Calvo R; Rodríguez-Sasiaín JM; Jiménez R; Trocóniz IF; Suárez E
Acta Anaesthesiol Scand; 1995 Nov; 39(8):1019-23. PubMed ID: 8607301
[TBL] [Abstract][Full Text] [Related]
7. Open channel and competitive block of nicotinic receptors by pancuronium and atracurium.
Löwenick CV; Krampfl K; Schneck H; Kochs E; Bufler J
Eur J Pharmacol; 2001 Feb; 413(1):31-5. PubMed ID: 11173060
[TBL] [Abstract][Full Text] [Related]
8. A single injection of botulinum toxin decreases the margin of safety of neurotransmission at local and distant sites.
Frick CG; Fink H; Blobner M; Martyn J
Anesth Analg; 2012 Jan; 114(1):102-9. PubMed ID: 22003222
[TBL] [Abstract][Full Text] [Related]
9. Ability of nondepolarizing neuromuscular blocking drugs to act as partial agonists at fetal and adult mouse muscle nicotinic receptors.
Fletcher GH; Steinbach JH
Mol Pharmacol; 1996 May; 49(5):938-47. PubMed ID: 8622644
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic-pharmacodynamic modeling of atracurium in intensive care patients.
Farenc C; Lefrant JY; Audran M; Bressolle F
J Clin Pharmacol; 2001 Jan; 41(1):44-50. PubMed ID: 11144993
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the neuromuscular blocking effect of cisatracurium and atracurium on the larynx and the adductor pollicis.
Kirov K; Motamed C; Decailliot F; Behforouz N; Duvaldestin P
Acta Anaesthesiol Scand; 2004 May; 48(5):577-81. PubMed ID: 15101851
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure.
Fahey MR; Rupp SM; Fisher DM; Miller RD; Sharma M; Canfell C; Castagnoli K; Hennis PJ
Anesthesiology; 1984 Dec; 61(6):699-702. PubMed ID: 6239574
[TBL] [Abstract][Full Text] [Related]
13. Blockade and activation of the human neuronal nicotinic acetylcholine receptors by atracurium and laudanosine.
Chiodini F; Charpantier E; Muller D; Tassonyi E; Fuchs-Buder T; Bertrand D
Anesthesiology; 2001 Apr; 94(4):643-51. PubMed ID: 11379686
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modeling of rocuronium in case of a decreased number of acetylcholine receptors: a study in myasthenic pigs.
De Haes A; Proost JH; De Baets MH; Stassen MH; Houwertjes MC; Wierda JM
Anesthesiology; 2003 Jan; 98(1):133-42. PubMed ID: 12502989
[TBL] [Abstract][Full Text] [Related]
15. Neuromuscular blocking properties of atracurium during sevoflurane or propofol anaesthesia in dogs.
Kastrup MR; Marsico FF; Ascoli FO; Becker T; Soares JH; Gomez de Segura IA
Vet Anaesth Analg; 2005 Jul; 32(4):222-7. PubMed ID: 16008719
[TBL] [Abstract][Full Text] [Related]
16. Chronic intraperitoneal endotoxin treatment in rats induces resistance to d-tubocurarine, but does not produce up-regulation of acetylcholine receptors.
Hinohara H; Morita T; Okano N; Kunimoto F; Goto F
Acta Anaesthesiol Scand; 2003 Mar; 47(3):335-41. PubMed ID: 12648201
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and dynamics of atracurium infusions after paediatric orthotopic liver transplantation.
Chow B; Bowden MI; Ho E; Weatherley BC; Bion JF
Br J Anaesth; 2000 Dec; 85(6):850-5. PubMed ID: 11732518
[TBL] [Abstract][Full Text] [Related]
18. [Effects of atracurium pretreatment with magnesium on speed of onset, duration, and recovery of neuromuscular blockade].
Wu HL; Ye TH; Sun L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Feb; 31(1):73-6. PubMed ID: 19317065
[TBL] [Abstract][Full Text] [Related]
19. Preanesthetic train-of-four fade predicts the atracurium requirement of myasthenia gravis patients.
Mann R; Blobner M; Jelen-Esselborn S; Busley R; Werner C
Anesthesiology; 2000 Aug; 93(2):346-50. PubMed ID: 10910480
[TBL] [Abstract][Full Text] [Related]
20. Prolonged administration of pyridostigmine impairs neuromuscular function with and without down-regulation of acetylcholine receptors.
Richtsfeld M; Yasuhara S; Fink H; Blobner M; Martyn JA
Anesthesiology; 2013 Aug; 119(2):412-21. PubMed ID: 23563362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
